Hepatotoxicity by tamsulosin / dutasteride: report of a probable case

• Autores: Yance, Stalin, Montes, Pedro
• Formato: artículo
• Fecha de Publicación: 2023
• Institución: Sociedad de Gastroenterología del Perú
• Repositorio: Revista de Gastroenterología del Perú
• Lenguaje: español
• OAI Identifier: oai:ojs.revistagastroperu.com:article/1544
• Enlace del recurso: https://revistagastroperu.com/index.php/rgp/article/view/1544
• Nivel de acceso: acceso abierto
• Materia: Hipertrofia benigna de próstata; Tamsulosina; Dutasteride; Hepartotoxicidad; Benign prostatic hypertrophy; Tamsulosin; Hepatotoxicity

Tamsulosin and dutasteride are drugs widely used to treat benign prostatic hypertrophy. having a good safety profile. There are few reports of liver injury associated with the use of tamsulosin; however, there are no reports of hepatic toxicity from the use of dutasteride and the combined use of tamsulosin/dutasteride. We present the case of a 64-year-old man who developed liver injury after the combined use of tamsulosin/dutasteride, developing a pattern of hepatocellular damage and acute hepatitis symptoms. Viral, autoimmune, and metabolic storage diseases of the liver were ruled out, as well as biliary pathology by means of abdominal ultrasound and resonance cholangiography. In the causality evaluation, CIOMS-RUCAM presented: 6 points (probable) and Naranjo: 4 points (possible). The patient presented a clinical and laboratory response after discontinuing the drug.